| Women's
Health Care |
 |
 Phase
II |
|
Phase
III |
|
Regulatory
Review |
| Alesse ® Acne labeling |
 |
 |
 |
| Premarin ® low dose Menopausal
symptoms |
|
|
|
| Osteoporosis |
 |
 |
 |
| Premarin ® /MPA low dose Menopausal
symptoms |
|
|
|
| Osteoporosis |
|
|
|
| Totelle ® Hormone replacement
therapy (EU) |
|
|
|
| Trimegestone/17 ß-estradiol Hormone
replacement therapy (EU) |
|
|
|
| Premarin ® /trimegestone Hormone
replacement therapy |
|
|
|
| Trimegestone/ethinyl estradiol Oral
contraceptive |
 |
|
|
| TSE-424 Postmenopausal osteoporosis |
|
|
|
| |
|
|
|
| Neuroscience Therapies |
|
|
|
| Effexor ® /Effexor ® XR Prevention
of relapse/recurrence of depression |
|
|
|
| Social anxiety disorder |
|
|
|
| Retigabine Anti-epileptic |
|
|
|
| |
|
|
|
| Vaccines/Infectious Diseases |
|
|
|
| FluMist ™ intranasal influenza vaccine
Frozen formulation |
|
|
|
| Liquid formulation |
|
|
|
| Prevnar ® Otitis media |
|
|
|
| 9-valent pneumococcal conjugate vaccine |
|
|
|
| 9-valent pneumococcal conjugate-meningococcal |
|
|
|
| Group
C conjugate vaccine |
|
|
|
| RSV subunit vaccine Prevention
of RSV infections |
|
|
|
| Zosyn ® Nosocomial pneumonia
q6h |
|
|
|
| GAR-936 Antibiotic for serious
infections |
|
|
|
| HCI-436 Treatment for hepatitis
C |
|
|
|
| |
|
|
|
| Musculoskeletal Therapies |
|
|
|
| Enbrel ® Disease modification
in early stage RA (EU) |
|
|
|
| rhBMP-2 Orthopaedic trauma
(long-bone |
|
|
|
| fractures
requiring surgery) |
|
|
|
| Spinal fusion |
|
|
|
| Dental/craniofacial |
|
|
|
| Osteonecrosis |
|
|
|
| Anti-IL-12 Rheumatoid arthritis
(joint with Abbott Laboratories) |
|
|
|
| |
|
|
|
| Internal Medicine |
|
|
|
| Protonix ® oral Maintenance
of erosive esophagitis (U.S.) |
|
|
|
| Zollinger-Ellison
Syndrome (U.S.) |
|
|
|
| Protonix ® I.V. Erosive
esophagitis (U.S.) |
|
|
|
| Zollinger-Ellison
Syndrome (U.S.) |
|
|
|
| Amiodarone aqueous Recurrent
ventricular fibrillation and |
|
|
|
| unstable
ventricular tachycardia |
|
|
|
| Enbrel ® Congestive heart
failure |
|
|
|
| PTP-112 Type II diabetes* |
|
|
|
| rPSGL-Ig Acute myocardial
infarction |
|
|
|
| |
|
|
|
| Immunology and Oncology |
|
|
|
| Rapamune ® Renal transplantation
- liquid (EU) |
|
|
|
| Maintenance
(U.S.) |
|
|
|
| Renal
transplantation - tablets (EU) |
|
|
|
| Liver
transplantation |
|
|
|
| rhIL-11 Subcutaneous therapy
for Crohn's disease |
|
|
|
| Mylotarg ® Relapsed acute
myeloid leukemia (EU) |
|
|
|
| Induction/consolidation
in acute myeloid leukemia |
|
|
|
| CCI-779 Various solid tumors |
|
|
|
| ERA-923 Breast cancer |
|
|
|
| |
Phase
II: Determination of safe and effective dosage for an experimental
medicine, generally conducted in hundreds of patients |
Phase
III: Determination of overall benefit/risk ratio for an experimental
medicine, generally conducted in thousands of patients |
Regulatory
Review: Evaluation of safety and efficacy data by governmental
regulatory agencies |
| |
| |
| |
A
Pipeline for Growth.
